Health Care/Hospital

Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

SUZHOU, China, Jan. 12, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the TST001 US P...

2022-01-12 15:15 2403

Biohacking by hydration: AQUIVIO IOT Smart Hydration Service keeps you hydrated and healthier all in one

TAIPEI, Jan. 12, 2022 /PRNewswire/ -- Improving our lifestyle can be achieved by many means, such as a physically active routine or healthier diet choices, yet probably none is as convenient and happening passively such as the daily hydration we choose. Preparing your personalized flavored and n...

2022-01-12 10:05 2258

ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease

* ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease * ABL301 uses ABL's Grabody-B platform technology to ef...

2022-01-12 07:59 2365

PostEra Closes $24M in New Financing to Advance Drug Discovery

BOSTON, Jan. 11, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. PostEra will use the proceeds to advance a series of ...

2022-01-11 22:00 2229

PostEra announces $260M multi-target strategic AI Lab collaboration with Pfizer

BOSTON, Jan. 11, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced the expansion of the company'sexisting strategic collaboration with Pfizer. The expanded multi-target research program will establish anAI Lab w...

2022-01-11 22:00 2362

Cambrex Celebrates its 40th Anniversary while Investing over $100 million in New Drug Substance Manufacturing Capacity

EAST RUTHERFORD, N.J., Jan. 11, 2022 /PRNewswire/ -- Cambrex recently celebrated the 40th anniversary of its founding in 1981. Following forty years of growth and transformation into a leading global contract development and manufacturing organization (CDMO), Cambrex continues its commitment to ...

2022-01-11 21:30 1696

Gift of Life Donor Program Breaks National Records in Saving Lives 705 Organ Donors, Leading to 1,732 Life-Saving Transplants

New CEO Richard Hasz Salutes Region – the Most Generous in the Nation for 14 Consecutive Years – and Team of "Heroes" for Extraordinary Commitment PHILADELPHIA, Jan. 11, 2022 /PRNewswire/ -- Gift of Life Donor Program once again leads the nation among all 57 U.S. organ procurement organizations (...

2022-01-11 21:05 1964

Clario and XingImaging expand partnership to deliver PET imaging clinical trials in China

BEIJING and PRINCETON, N.J., Jan. 11, 2022 /PRNewswire/ -- Clario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their pa...

2022-01-11 21:00 1900

SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study

BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT0...

2022-01-11 20:27 1578

China's 2021 U.S. Patent Grants Surged, Even as Total Patent Awards Trended Downward, According to Analysis by IFI CLAIMS

2021 Rankings Shed Light on Corporate R&D Priorities: Telemedicine, Supply Chain Efficiencies, E-Cigs and Artificial Intelligence Among Hottest Areas of Activity NEW HAVEN, Conn., Jan. 11, 2022 /PRNewswire/ -- Enhancements in telemedicine, more hardy grains to feed the world in a time of climate...

2022-01-11 18:00 1383

Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...

2022-01-11 16:30 2661

Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster

TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...

2022-01-11 15:15 2097

SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections

COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabli...

2022-01-11 14:29 1241

MGI Aims to Boost its Market Share through Participation at Expo 2020 Dubai's Guangdong Week

DUBAI, UAE, Jan. 11, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) is aiming to boost its market share in theMiddle East and Asia through participation at Guangdong Week, a dedicated event taking place at the world exhibition's China Pavilion fromJanuary 11-13. The ...

2022-01-11 14:00 1769

Team8: New parental control for healthy children

TAIPEI, Jan. 11, 2022 /PRNewswire/ -- Team8 is an universe & Operating Systems for kids (6-12 years old). Give a new life to any Android phone (old or new) and secure it for kids combining Fun, Health, Education & Security. Kids can create and manage their own super-hero (name, costume, abilities...

2022-01-11 10:05 2048

Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy

SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy , the US-based enterprise analytics platform, supportedPfizer, an American multinational pharmaceutical and biotechnology corporation, to usher in a future of sustainable data culture. With the help of solut...

2022-01-11 09:30 2092

Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod

* Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes * With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy * Frequent testing wit...

2022-01-11 09:00 2088

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication. The Phase II clinical trial (ClinicalTrials.gov Identifier: NCT051...

2022-01-11 08:30 2510

Dr. Ivan Puah Highlights The Significant Impact Of Covid That Changes Our Priority In Life

SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- The current pandemic has raised more awareness of the importance of health and better care of oneself. Dr.Ivan Puah, Medical Director at Amaris B. Clinic shares how people's lifestyles and priorities have changed since Covid-19 started. 01. Losing we...

2022-01-11 06:44 1642

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmace...

2022-01-11 05:30 3197
1 ... 241242243244245246247 ... 554